Zacks Investment Research downgraded OncoCyte Corp (NYSE:OCX) to Sell in a report released today.
- Updated: September 24, 2016
Zacks Investment Research has downgraded OncoCyte Corp (NYSE:OCX) to Sell in a report released on 9/22/2016.
Yesterday OncoCyte Corp (NYSE:OCX) traded 7.14% higher at $4.58. The company’s 50-day moving average is $4.05 and its 200-day moving average is $4.44. The last stock close price is up 11.42% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 26,918 shares of the stock were exchanged, up from an average trading volume of 24,034
See Chart Below
OncoCyte Corp has a 52 week low of $2.45 and a 52 week high of $10.24 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 2 firms have reported on the stock. The consensus target price is $11.50 with 1 firm rating the stock a strong buy, 1 firm rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About OncoCyte Corp (NYSE:OCX)
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment. Its initial focus will be confirmatory diagnostics, utilizing liquid biopsy technology, for use in conjunction with imaging to confirm initial diagnoses within certain oncology indications. In addition, it will be developing screening diagnostics as replacements for screening imaging procedures. For some indications, it will also be pursuing the probability of recurrence of a specific cancer through the development of prognostics or companion diagnostics that help a physician determine which therapy is the optimal treatment for the patient. It offers diagnostic tests for lung, breast and bladder cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.